Denmark’s largest company, Novo Nordisk, has come up with an unusual perk for employees.
This was reported by Bloomberg News Agency.
Novo Nordisk is behind the slimming drug Wegovy, and offers this drug – just like its other products – for free to its employees. The company stresses that those wishing to benefit from the offer must obtain a doctor’s approval and a prescription. In Denmark, this means you must be overweight and have a BMI of more than 30.
The letter from the company also stated that employees must pay tax on the medicine they use. The offer comes despite the company’s struggle to meet the demand in the American market for weight loss drugs.
Read on E24+
David Jurek has seen his colleagues drunk at work. This is how you should act if you have doubts
The Danish pharmaceutical giant recently became the largest company in Europe by market capitalization. This progress is due, among other things, to the success of anti-obesity drugs.
The Danish manufacturer’s profits rose sharply thanks to strong demand for the drugs Ozempic and Wegovy.
The first is a drug for type 2 diabetes, but thanks to the support of American celebrities, it has become very popular as a slimming agent.
Wegovy contains the same active ingredient, but is marketed to treat obesity.
This is what is now offered to obese employees.
– Wegovy could become a gold mine, analyst Søren Luntoft Hansen from Danish Sydbank told E24 this summer.
Norway is one of the few countries in Europe where you can get Wegovy, along with Denmark. According to Bloomberg, it is estimated that more than 100,000 Danes have used the drug since it was put on the market about a year ago.
Other countries where the drug is available are Germany and Great Britain.
According to the Danish Medicines Agency No progress Wegovy on blue prescription. The reason is that it is “expensive compared to the documented health effects.” The cost of the medication is approximately NOK 36,000 per year.
Larger than Denmark’s GDP
The company is now larger than the entire GDP of Denmark, and they were recently known to be handing over $67 billion to increase production.
The investment will increase capacity in the entire value chain. Among other things, the company will be able to produce GLP-1 products used against obesity. These products help create a feeling of fullness, and have achieved great success for the company recently.
Novo Nordisk is celebrating 100 years this year and has 23,000 employees.